FIELD: medicine.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and concerns production of mexiprim antipsoriatic agent containing mexiprim (2 ethyl-6-methyl-3-hydroxypyridine succinate) as an active material and additionally sepygel 305, merytole 312, hermabene 11, cathone CG, glycerine, urea and water in specified ratio. The agent can represent gel to be used within stationary and incomplete disease remission, as well as for skin care in apparent age changes by applying gel on pathological skin rash twice a day within 3-4 weeks.
EFFECT: in all cases clinical tests show considerable reduction of peeling, absence of skin tightness, healing of small cracks, humidifying sensation.
3 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SKIN DISEASES TREATMENT AGENT | 2007 |
|
RU2356536C1 |
| METHOD OF TREATING PSORIASIS IN CHILDREN | 2006 |
|
RU2401123C2 |
| AGENT FOR TREATMENT OF WOUNDS, BURNS AND INFLAMMATORY SKIN DISEASES | 2020 |
|
RU2744545C1 |
| AGENT FOR WOUNDS, BURNS AND INFECTIOUS INFLAMMATORY DISEASES OF SKIN, APPENDAGES AND MUCOUS MEMBRANES | 2010 |
|
RU2452475C2 |
| METHOD OF TREATING ATOPIC DERMATITIS | 2008 |
|
RU2363440C1 |
| METHOD OF EXTERNAL TREATMENT OF LOCALISED PSORIASIS | 2007 |
|
RU2341301C2 |
| METHOD OF TRANSDEMAL DRUG INTRODUCTION IN PSORIASIS TREATMENT WITH USING ELECTRET APPLICATORS | 2008 |
|
RU2386456C1 |
| LIPID COMPLEX FOR TREATMENT OF CHRONIC DERMATOSES | 1998 |
|
RU2159118C2 |
| METHOD OF TREATING PATIENTS WITH PSORIASIS | 2009 |
|
RU2412681C2 |
| METHOD OF TREATING INFLAMMATORY PERIODONTAL AND ORAL MUCOSAL DISEASES | 2014 |
|
RU2552307C1 |
